Bayer wins FDA approval for Gadavist

The injection has been approved to assess myocardial perfusion and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). The approval is based on two prospective, open-label, non-randomised, multi-centre, blinded-read Phase III studies, which investigated the diagnostic results of gadobutrol-enhanced cardiac MRI for the evaluation of significant CAD. Cardiac MRI is a medical imaging technology for the non-invasive assessment of the function and structure of the cardiovascular system, and the approval is a “landmark” for making the “validated, non-invasive method available to healthcare professionals to evaluate their patients for the most common form of heart disease in the world,” according to Daniel Berman, chief of cardiac imaging and nuclear cardiology at the Cedars-Sinai Heart Institute. The technique is derived from and based on the same basic principles as MRI, however with optimisation for use in the cardiovascular system.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!